Non-Profit Advocates for Affordable Prescription Drug Prices Call on Congress to Increase Competition and Hold Big Pharma Accountable In case you missed it, Tahir Amin and Priti Krishtel, co-executive directors of the Initiative for Medicines, Access & Knowledge (I-MAK), published an op-ed in The Hill calling on Congress to lower prescription drug prices by holding […]
New Matrix Global Advisors Report Shines Light on Cost of Big Pharma’s Patent Abuse A new report released on Thursday by Matrix Global Advisors and commissioned by the Coalition for Affordable Prescription Drugs, “Patent Thickets and Lost Drug Savings,” examines the cost of Big Pharma’s use of ‘patent thickets’ on patients and the U.S. healthcare […]
Analysis Finds Drug Companies Increased Prices Faster Than the Rate of Inflation on 70 of the 93 Best-Selling Part B Prescription Drugs In case you missed it, researchers affiliated with Brigham and Women’s Hospital and Harvard University published an analysis in The Journal of the American Medical Association (JAMA) which found that the Medicare Part B program […]
Brand Name Drug Companies Setting Egregious Prices on New Products Not Justified by Clinical Value for Patients In case you missed it, Reuters released a new analysis that found the median annual price among drugs approved by the U.S. Food and Drug Administration (FDA) in 2022 exceeded $200,000. In the second half of 2022, the median price […]
Congressional Probe Concludes Biogen Set Egregious Price Tag on Aduhelm to Maximize Profits, Knew Price Tag Could Lead to Affordability Issues for Patients In case you missed it, the U.S. House Committee on Oversight and Reform and the U.S. House Committee on Energy and Commerce recently completed an 18-month investigation into the egregious pricing of […]
Get the Facts on Big Pharma’s Year of Out-of-Control Launch Prices, Price Hikes, Anti-Competitive Tactics and Massive Spending on a Debunked Blame Game Despite unprecedented scrutiny of Big Pharma’s egregious pricing and anti-competitive practices and major progress in Washington toward holding the pharmaceutical industry accountable, Big Pharma continued to double down on a business-as-usual approach […]
Amgen and Horizon Therapeutics Eye Merger As Both Continue to Hike Prices on Blockbuster Prescription Drugs On Monday, Big Pharma giant Amgen announced plans to acquire Horizon Therapeutics for $27.8 billion, making it the largest healthcare merger of the year. Horizon Therapeutics is known for several rare autoimmune and severe inflammatory disease drugs, including Tepezza, […]
Regeneron Co-Founder Says, “Forget About That” When Pressed on How Patients and the U.S. Health Care System Will Afford Treatments Priced in the Millions of Dollars On Wednesday, Regeneron Pharmaceuticals co-founder and Chief Scientific Officer George Yancopoulos brazenly dismissed concerns with the affordability of Big Pharma products priced in the millions of dollars during a […]
Brand Name Drug Companies Continue Raising Prices on Blockbuster Products With No Increase in Clinical Value for Patients In case you missed it, the Institute for Clinical and Economic Review (ICER) released new data showing Big Pharma continues to repeatedly raise list prices on blockbuster drugs in the U.S. with no substantial increase in their clinical benefit […]
Big Pharma Giant Wants New Patents for Formulation Changes That Won’t Improve Clinical Benefit of Cancer Drug — Adding to Existing Patent Thicket of 129 Filed Applications On Friday, Big Pharma giant Merck announced that it will seek new patents on its blockbuster cancer drug Keytruda, which last year brought in over $17 billion for […]